These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 29100409)

  • 21. Association between BIM deletion polymorphism and clinical outcome of EGFR-mutated NSCLC patient with EGFR-TKI therapy: A meta-analysis.
    Ma JY; Yan HJ; Gu W
    J Cancer Res Ther; 2015; 11(2):397-402. PubMed ID: 26148607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro splicing analysis showed that availability of a cryptic splice site is not a determinant for alternative splicing patterns caused by +1G-->A mutations in introns of the dystrophin gene.
    Habara Y; Takeshima Y; Awano H; Okizuka Y; Zhang Z; Saiki K; Yagi M; Matsuo M
    J Med Genet; 2009 Aug; 46(8):542-7. PubMed ID: 19001018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting novel human transient receptor potential ankyrin 1 splice variation with splice-switching antisense oligonucleotides.
    Huang H; Tay SH; Ng W; Ng SY; Soong TW
    Pain; 2021 Jul; 162(7):2097-2109. PubMed ID: 33938719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative effect of imatinib and ponatinib on autophagy and miRNome in chronic myeloid leukemia.
    Kayabasi C; Okcanoglu TB; Yelken BO; Asik A; Susluer SY; Avci CB; Saydam G; Gunduz C
    Gene; 2017 Dec; 637():173-180. PubMed ID: 28942039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.
    Kuroda J; Puthalakath H; Cragg MS; Kelly PN; Bouillet P; Huang DC; Kimura S; Ottmann OG; Druker BJ; Villunger A; Roberts AW; Strasser A
    Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14907-12. PubMed ID: 16997913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proteomic analysis of imatinib-resistant CML-T1 cells reveals calcium homeostasis as a potential therapeutic target.
    Toman O; Kabickova T; Vit O; Fiser R; Polakova KM; Zach J; Linhartova J; Vyoral D; Petrak J
    Oncol Rep; 2016 Sep; 36(3):1258-68. PubMed ID: 27430982
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zinc-induced modulation of SRSF6 activity alters Bim splicing to promote generation of the most potent apoptotic isoform BimS.
    Hara H; Takeda T; Yamamoto N; Furuya K; Hirose K; Kamiya T; Adachi T
    FEBS J; 2013 Jul; 280(14):3313-27. PubMed ID: 23648111
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
    Halbach S; Hu Z; Gretzmeier C; Ellermann J; Wöhrle FU; Dengjel J; Brummer T
    Cell Commun Signal; 2016 Feb; 14():6. PubMed ID: 26912052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rescue of mis-splicing of a common
    Feng P; Xu Z; Chen J; Liu M; Zhao Y; Wang D; Han L; Wang L; Wan B; Xu X; Li D; Shu Y; Hua Y
    Mol Ther Nucleic Acids; 2022 Jun; 28():280-292. PubMed ID: 35433113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism of synergy of BH3 mimetics and paclitaxel in chronic myeloid leukemia cells: Mcl-1 inhibition.
    Song T; Chai G; Liu Y; Xie M; Chen Q; Yu X; Sheng H; Zhang Z
    Eur J Pharm Sci; 2015 Apr; 70():64-71. PubMed ID: 25596561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene.
    Errington SJ; Mann CJ; Fletcher S; Wilton SD
    J Gene Med; 2003 Jun; 5(6):518-27. PubMed ID: 12797117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia.
    Milojkovic D; Apperley J
    Clin Cancer Res; 2009 Dec; 15(24):7519-7527. PubMed ID: 20008852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors.
    Lee JY; Ku BM; Lim SH; Lee MY; Kim H; Kim M; Kim S; Jung HA; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2015 Jun; 10(6):903-9. PubMed ID: 26001141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential expression and alternative splicing of cell cycle genes in imatinib-treated K562 cells.
    Liu J; Lin J; Huang LF; Huang B; Xu YM; Li J; Wang Y; Zhang J; Yang WM; Min QH; Wang XZ
    Tumour Biol; 2015 Sep; 36(10):8127-36. PubMed ID: 25983000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alternative splice forms of CTLA-4 induced by antisense mediated splice-switching influences autoimmune diabetes susceptibility in NOD mice.
    Mourich DV; Oda SK; Schnell FJ; Crumley SL; Hauck LL; Moentenich CA; Marshall NB; Hinrichs DJ; Iversen PL
    Nucleic Acid Ther; 2014 Apr; 24(2):114-26. PubMed ID: 24494586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
    Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
    Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pro-apoptotic effects of splice-switching oligonucleotides targeting Bcl-x pre-mRNA in human glioma cell lines.
    Li Z; Li Q; Han L; Tian N; Liang Q; Li Y; Zhao X; Du C; Tian Y
    Oncol Rep; 2016 Feb; 35(2):1013-9. PubMed ID: 26718027
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases.
    Chen S; Heendeniya SN; Le BT; Rahimizadeh K; Rabiee N; Zahra QUA; Veedu RN
    BioDrugs; 2024 Mar; 38(2):177-203. PubMed ID: 38252341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
    Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
    Wong SF; Mirshahidi H
    Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.